Organic Process Research & Development 2005, 9, 583−592
Synthesis of Methyl 1-(2,3,5-Tri-O-acetyl-â-L-ribofuranosyl)-1,2,4-
triazole-3-carboxylate from L-Ribose: From a Laboratory Procedure to a
Manufacturing Process
Pingsheng Zhang,* Zhiming E. Dong, and Thomas P. Cleary
Pharmaceutical Process DeVelopment, Roche Carolina Inc., 6173 East Old Marion Highway,
Florence, South Carolina 29506, U.S.A.
Scheme 1. Kilo-lab synthesis of 1
Abstract:
A two-step manufacturing process for methyl 1-(2,3,5-tri-O-
acetyl-â-
developed. In step 1,
of 1,2,3,5-tetra-O-acetyl-
L
-ribofuranosyl)-1,2,4-triazole-3-carboxylate (1) was
-ribose was converted to a â/r mixture
-ribofuranoses (2 and 4). The step
L
L
contained four chemical transformations and was completed
in “one-pot” in approximately 95% yield. The crude step 1
product was reacted with methyl 1,2,4-triazole-3-carboxylate
(3) in step 2 to produce 1. The successful utilization of both
isomers (2 and 4) in step 2 offered advantages of higher overall
yield and a much simplified process by eliminating the isolation
of pure 2. The process was successfully scaled up to the pilot
plant and subsequently in a manufacturing campaign using
commercial production facilities.
in the literature was tedious, containing 18 extractions and
8 distill-to-dryness operations, and was deemed not suitable
for scale-up. Part of the reason for the process being
cumbersome was the complex nature of the conversion. In
most solvents ribose exists as an equilibrium mixture of five
isomers: one acyclic form, two ribofuranoses, and two
ribopyranoses (Scheme 2, R ) H).3 In early studies, direct
acetylation of ribose under different conditions formed a
mixture of up to five products, with the ribopyranoses being
the major component in most cases.4 Therefore, to achieve
an efficient conversion of ribose to ribofuranoses, a stepwise
approach had to be adopted. It was reported5 that metha-
nolyses of most of the pentoses under acidic conditions
afforded the kinetically favored methyl furanosides first, and
then the furanosides gradually converted to the thermody-
namically favored pyranosides until an equilibrium was
reached (Scheme 2, R ) CH3). If the methanolysis was
conducted under mild conditions and the equilibrium was
stopped before significant amounts of the pyranosides were
formed, the furanosides could be obtained as the major
products. Based on this approach, a strategy to convert
D-ribose to 1,2,3,5-tetra-O-acetyl-â/R-D-ribofuranoses was
developed by Guthrie et al.6 As indicated in Scheme 3,
D-ribose was first converted to methyl ribofuranosides
(methanolysis) in methanol with a catalytic amount of strong
acid. The ribofuranosides were then converted to methyl
2,3,5-tri-O-acetyl-â/R-D-ribofuranosides (acetylation) by
reacting with acetic anhydride under basic conditions,
followed by acetolysis in acetic acid and acetic anhydride
to afford 1,2,3,5-tetra-O-acetyl-â/R-D-ribofuranoses. The
Introduction
Methyl 1-(2,3,5-tri-O-acetyl-â-L-ribofuranosyl)-1,2,4-tria-
zole-3-carboxylate (1) was an intermediate for the synthesis
of Levovirin,1 which was developed as an antiviral agent to
treat hepatitis C. In the early kilo-lab campaigns, 1 was
prepared from 1,2,3,5-tetra-O-acetyl-â-L-ribofuranose (2), as
illustrated in Scheme 1. Commercially available compound
2 was very expensive; therefore the cost of goods became a
serious issue for the commercial success of the drug. To
overcome this problem, we decided to introduce an in-house
production of 2 from considerably less expensive L-ribose.
Only one literature procedure was found for the conver-
sion of L-ribose to compound 2.2 The procedure described
* Corresponding author. Telephone: (843)-629-4241. Fax: (843)-629-4128.
E-mail: Pingsheng.zhang@roche.com.
(3) (a) Lichtenthaler, F. D.; Breunig, J.; Fischer, W. Tetrahedron Lett. 1971,
12, 2825. (b) Bishop, C. T.; Cooper, F. P. Can. J. Chem. 1963, 41, 2743.
(c) Smirnyagin, V.; Bishop, C. T. Can. J. Chem. 1968, 46, 3085.
(4) (a) Furneaux, R. H.; Rendle, P. M.; Sims, I. M. J. Chem. Soc., Perkin Trans.
1 2000, 2011. (b) Brown, G. B.; Davoll, J.; Lowy, B. A. Biochem. Prep.
1955, 4, 70. (c) Zhang, P.; Dong, Z. E. Unpublished results.
(5) (a) Ferrier, R. J.; Hatton, L. R. Carbohydr. Res. 1968, 6, 75. (b) Mowery,
D. F. J. Am. Chem. Soc. 1955, 77, 1667. (c) Bishop, C. T.; Cooper, F. P.
Can. J. Chem. 1961, 40, 224; also see: ref 4b and c.
(1) For biologic properties of Levovirin, see: (a) Fang, C.; Srivastava, P.; Lin,
C. J. Appl. Toxicol. 2003, 23, 453. (b) Lin, C.; Luu, T.; Lourenco, D.; Yeh,
L. T.; Lau, J. Y. N. J. Antimicrob. Chemother. 2003, 51, 93. (c) Watson, J.
Curr. Opin. InVest. Drugs 2002, 3, 680. (d) Tam, R. PCT Int. Appl. WO
01/046212. (e) Zeytinoglu, F. PCT Int. Appl. WO 01/045/642. (f) Lin, C.;
Lau, J. Y. N. J. Pharm. Biomed. Anal. 2002, 30, 239.
(2) (a) Ramasamy, K. S.; Tam, R. C.; Bard, J.; Averett, D. R. J. Med. Chem.
2000, 43, 1019. (b) Ramasamy, K. S.; Hills, L.; Tam, R.; Averett, D. U.S.
Patent 6,130,326, 2000.
(6) Guthrie, R. D.; Smith, S. C. Chem. Ind. (London) 1968, 547.
10.1021/op050051m CCC: $30.25 © 2005 American Chemical Society
Published on Web 08/04/2005
Vol. 9, No. 5, 2005 / Organic Process Research & Development
•
583